<DOC>
	<DOCNO>NCT01205386</DOCNO>
	<brief_summary>The purpose study determine CROSSER CTO Recanalization System facilitate successful cross Chronic Total Occlusions Central lumen Superficial Femoral Artery ( SFA ) . A Chronic Total Occlusion ( CTO ) define 100 % narrowing artery , angiographically detectable antegrade blood flow , assessment lesion existence minimum 30 day . This study enroll 100 patient 8 clinical site . The CROSSER CTO Recanalization System clear commercialization US Food &amp; Drug Administration . This study also involve image device call IVUS ( Intravascular Ultrasound Imaging ) catheter . This device clear commercialization US Food Drug Administration study clear intend use . The IVUS catheter use generate real-time image artery , allow evaluation artery occlusion cross . This post-market registry .</brief_summary>
	<brief_title>Crosser Enters The Right Arterial Lumen</brief_title>
	<detailed_description />
	<criteria>Patient must objective evidence low extremity ischemia schedule undergo endovascular recanalization . Occluded artery must native superficial femoral artery . Patient must totally occlusive lesion classify angiographically absolute ( 100 % occlusion flow ) . Patient 's target vessel occlusion length ≤ 30 cm . Patient 's reference vessel diameter great equal 3.0mm . Patient must acceptable candidate PTA , peripheral artery bypass surgery peripheral artery stent implantation . Female patient child bear potential must negative pregnancy test within 72 hour prior study procedure . Patient guardian must inform nature study , agree provision , provide write informed consent . Patient ≥ 18 year age . Patient hypersensitivity contraindication aspirin , heparin radiographic contrast agent adequately premedicated . The patient require immediate treatment one occlude vessel , combination graft native vessel . Patient 's occlusion flush occlusion initiate less 2cm ostium . Patient plan infrainguinal intervention schedule within 30 day index procedure . The patient currently participate another investigational drug device trial may conflict study data collection complete entire followup period . Patient collateral flow distal occlusion . Patient 's target occlusion dissection occur within past 60 day cause guidewire attempt . Patient history bleeding diatheses , coagulopathy refuse blood transfusion case emergency . Patient suffer recent ( within past 6 month ) stroke transient ischemic neurological attack ( TIA ) . Patient suffer recent ( within past 6 month ) significant gastrointestinal ( GI ) bleeding . Patient medical illness ( i.e. , cancer congestive heart failure ) may cause patient noncompliant protocol , confound data interpretation associate lifeexpectancy less 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>CTO</keyword>
	<keyword>peripheral artery occlusive disease</keyword>
	<keyword>PAOD</keyword>
	<keyword>SFA</keyword>
	<keyword>superficial femoral artery</keyword>
</DOC>